<?xml version='1.0' encoding='utf-8'?>
<document id="20233177"><sentence text="Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment."><entity charOffset="54-66" id="DDI-PubMed.20233177.s1.e0" text="methotrexate" /></sentence><sentence text="To investigate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550, a novel Janus kinase (JAK) inhibitor in development as a therapy for rheumatoid arthritis (RA), to determine the effects of multiple doses of CP-690,550 on the PK of MTX, and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX"><entity charOffset="30-42" id="DDI-PubMed.20233177.s2.e0" text="methotrexate" /><entity charOffset="44-47" id="DDI-PubMed.20233177.s2.e1" text="MTX" /><entity charOffset="259-262" id="DDI-PubMed.20233177.s2.e2" text="MTX" /><entity charOffset="358-360" id="DDI-PubMed.20233177.s2.e3" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e0" e2="DDI-PubMed.20233177.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e0" e2="DDI-PubMed.20233177.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e0" e2="DDI-PubMed.20233177.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e0" e2="DDI-PubMed.20233177.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e1" e2="DDI-PubMed.20233177.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e1" e2="DDI-PubMed.20233177.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e1" e2="DDI-PubMed.20233177.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e2" e2="DDI-PubMed.20233177.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20233177.s2.e2" e2="DDI-PubMed.20233177.s2.e3" /></sentence><sentence text="" /><sentence text="This was a fixed-dose drug-drug interaction study" /><sentence text=" Twelve patients diagnosed with RA for at least 6 months were enrolled in a Phase I, open-label study of the PK of multiple doses of CP-690,550 (30 mg b" /><sentence text="i" /><sentence text="d" /><sentence text=") and single doses of MTX (15-25 mg per week)"><entity charOffset="22-25" id="DDI-PubMed.20233177.s8.e0" text="MTX" /></sentence><sentence text="" /><sentence text="All patients completed the study and were evaluated for PK and safety" /><sentence text=" CP-690,550 exposure was not affected by co-administration with MTX; AUC(12) ratio (CP-690,550 + MTX/CP-690,550) was 103"><entity charOffset="64-67" id="DDI-PubMed.20233177.s11.e0" text="MTX" /><entity charOffset="97-99" id="DDI-PubMed.20233177.s11.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20233177.s11.e0" e2="DDI-PubMed.20233177.s11.e0" /><pair ddi="false" e1="DDI-PubMed.20233177.s11.e0" e2="DDI-PubMed.20233177.s11.e1" /></sentence><sentence text="06% [90% confidence interval (CI) 99" /><sentence text="00, 107" /><sentence text="29]" /><sentence text=" MTX exposure decreased by 10%; AUC(12) ratio (CP-690,550 + MTX/MTX) was 89"><entity charOffset="1-3" id="DDI-PubMed.20233177.s15.e0" text="MTX" /><entity charOffset="60-62" id="DDI-PubMed.20233177.s15.e1" text="MTX" /><entity charOffset="64-66" id="DDI-PubMed.20233177.s15.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20233177.s15.e0" e2="DDI-PubMed.20233177.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20233177.s15.e0" e2="DDI-PubMed.20233177.s15.e1" /><pair ddi="false" e1="DDI-PubMed.20233177.s15.e0" e2="DDI-PubMed.20233177.s15.e2" /><pair ddi="false" e1="DDI-PubMed.20233177.s15.e1" e2="DDI-PubMed.20233177.s15.e1" /><pair ddi="false" e1="DDI-PubMed.20233177.s15.e1" e2="DDI-PubMed.20233177.s15.e2" /></sentence><sentence text="53% (90% CI 77" /><sentence text="38, 103" /><sentence text="57), which was not considered clinically significant" /><sentence text=" Co-administration of CP-690,550 and MTX was safe and well tolerated"><entity charOffset="37-40" id="DDI-PubMed.20233177.s19.e0" text="MTX" /></sentence><sentence text=" There were no serious adverse events or withdrawals from the study and there was no trend in the incidence or severity of adverse events across treatments" /><sentence text="" /><sentence text="Co-administration of CP-690,550 and MTX was safe and well tolerated"><entity charOffset="36-39" id="DDI-PubMed.20233177.s22.e0" text="MTX" /></sentence><sentence text=" There was no clinically significant effect on the PK profile of either drug" /><sentence text=" Therefore, dose adjustments should not be required when co-administering CP-690,550 and MTX"><entity charOffset="89-91" id="DDI-PubMed.20233177.s24.e0" text="MTX" /></sentence><sentence text="" /></document>